The STAT3 inhibitor TTI-101 (Tvardi Therapeutics, Incorporated, USA) is now undergoing testing in a phase I clinical trial in patients with advanced cancers (clinicaltrials.gov ID NCT03195699) [7]. This evidence concerns the gene STAT3 and cancer.